- 基本信息
|
导师姓名：
|
虞永峰
|
学科代码：
|
100214
|
|
|
性别：
|
男
|
学科名称：
|
肿瘤学
|
|
培养单位：
|
附属胸科医院
|
三级学科
|
|
|
导师类型：
|
硕士生导师
|
专业领域名称：
|
肿瘤学 专业学位
|
|
联系方式：
|
|
专业领域代码：
|
105121
|
|
邮编：
|
|
邮箱地址：
|
yuyongfeng212@sina.com
|
- 研究方向 (点击浏览详细信息)
- 社会任职
| |
|
上海市抗癌协会胸部肿瘤委员会青年委员
|
|
中国医药教育协会肿瘤免疫治疗专业委员会秘书长
|
|
上海市药学会抗生素专业委员会委员
|
|
CSCO青年委员
|
|
上海市医学会肿瘤专科分会青年会副主任委员
|
|
中国抗癌协会肺癌专业委员会青委会副主任委员
|
|
《Journal of Thoracic Disease》(SCI收录) 特邀审稿人
|
|
国际肺癌研究协会（IASLC）会员（会员号：414443）
|
|
中国健康促进基金会肺癌专业委员会常委
|
|
《解放军医学杂志》特邀审稿人
|
|
中国抗癌协会（CSCO）会员（会员号：20066339）
|
|
上海市医学会肿瘤专科分会青年会副主任委员
|
- 科研项目
| Y-HR2020MS-0982 | 免疫治疗在EGFR-TKI 治疗后PD-L1 高表达晚期NSCLC 患 者疗效探索 | CSCO恒瑞肿瘤研究基金 |
2022-12~2025-12
|
15万元
| 课题负责人 |
| 82172633 | FGFR1-wnt-β-catenin轴调控肺鳞癌细胞干性表型，侵袭转移和免疫逃逸的分子机制 | 国家自然科学基金面上项目 |
2022-01~2025-12
|
54万元
| 课题负责人 |
| 16431903203 | c-Met激酶选择性抑制剂SPH3348的临床前开发 | 上海市科委“科技创新行动计划”生物医药领域科技支撑项目 |
2016-07~2019-09
|
15万元
| 子课题负责人 |
| 81201692 | 基于活性的蛋白质谱分析在早期非小细胞肺癌分子分型中的运用 | 国家自然科学基金青年项目 |
2013-01~2015-12
|
23万元
| 课题负责人 |
- 学术论文
|
, Jianya Zhou, Xingya Li,Koichi Goto,Xuhong Min,Kazumi Nishino,Jiuwei Cui,Lin Wu,Jun Sakakibara, Yongqian Shu, Xiaorong Dong,Lu Li,Yasuto Yoneshima,Chengzhi Zhou,Xiaoling Yiping Zhang,Dingzhi Huang,Aimin Zang,Wei Zhang,Xiuwen Wang,Li Zhang,Chong Bai,Jian Fang,Lejie Cao, Yanqiu Zhao,Yan Yu,Meiqi Shi,Diansheng Zhong,Fugen Li, Meng Li,Qiuxia Wu,Jun Zhou,Minghui Sun,and Shun Lu
|
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre,single-arm, open-label, phase 1b/2 trial
|
eClinicalMedicine
|
2023
|
59: 101952
|
|
, Fanfan Zhu , Wenxin Zhang ,Shun Lu.
|
Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase- Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison.
|
Jounal of Clinical Medicine
|
2022
|
11,2963
|
|
, Jie Qian, Lan Shen, Wenxiang Ji, Shun Lu
|
Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists
|
Ann Transl Med
|
2022
|
10(2):41
|
|
Xinghao Ai,, Jun Zhao, Wang Sheng, Jing Bai, Zaiwen Fan, Xuemei Liu,Wenxiang Ji, Rongrong Chen ,2Shun Lu
|
Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting
|
TherapeuTic advances in MedicalOncology
|
2022
|
14:1-14
|
|
, Yongxin Ren, Jian Fang, Lejie Cao, Zongan Liang, Qisen Guo, Sen Han, Zimei Ji,Ye Wang, Yulan Sun, Yuan Chen, Xingya Li, Hua Xu, Jianying Zhou, Liyan Jiang, Ying Cheng, Zhigang Han, Jianhua Shi, Gongyan Chen, Rui Ma, Yun Fan, Sanyuan Sun, Longxian Jiao, Xiaoyun Jia, Linfang Wang, Puhan Lu, Qian Xu, Xian Luo, Weiguo Su, Shun Lu
|
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study
|
Therapeutic Advances in Medical Oncology
|
2022
|
14:1–15
|
|
, Luan Luan, Fanfan Zhu, Peng Dong, LiHeng Ma, Lanting Li, Lan Gao, Shun Lu
|
Modelled economic analysis for dacomitinib– is it cost effective in treating patients with EGFR-mutation-positive non-small-cell lung cancer in China
|
Frontiers in Oncology
|
2021
|
11:564234
|
|
, Lan Shen, Wenxiang Ji, Shun Lu
|
Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing
|
Ann Transl Med
|
2021
|
9(2):140
|
|
, Jie Qian, Lan Shen, Wenxiang Ji, Shun Lu.
|
Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing
|
International Journal of Medical Sciences
|
2021
|
18(6): 1510-1518
|
|
Jie Qian, Rongrong Chen, Ruiying Zhao, Yuchen Han,
|
Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma
|
Frontiers in Oncology
|
2020
|
10:607130
|
|
, Qiuxiang Ou,Xue Wu,Hairong Bao,Yan Ding,Yang W. Shao,Shun Lu
|
Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer
|
Lung Cancer
|
2019
|
127(1):19-24.
|
|
Shun Lu,,Ziming Li,Ruoying Yu,Xue Wu,Hairong Bao,Yan Ding, Yang W. Shao,Hong Jian
|
EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer
|
J Thorac Oncol
|
2019
|
14(4):732-736
|
|
Rongrong Chen, Xiaohua Yang,Zhengping Ding,Lei Zhu,Shun Lu,
|
Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes
|
Eur J Surg Oncol
|
2019
|
45(5):838-844
|
|
Rongrong Chen, Zhengping Ding, Lei Zhu, Shun Lu,
|
Correlation of Clinicopathologic Features and Lung Squamous Cell Carcinoma Subtypes According to the 2015 WHO Classification
|
Eur J Surg Oncol
|
2017
|
43(12):2308-2314.
|
|
, Jian H, Shen L, Zhu L, Lu S
|
Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: A study of 2268 cases
|
Eur J Surg Oncol
|
2016
|
2016,42(11):1714-1719
|
|
, Ding Z, Jian H, Shen L, Zhu L, Lu S
|
Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma.
|
Cancer Med
|
2016
|
2016,5(9):2323-2331
|
|
, Zhengping Ding, Lei Zhu, Haohua Teng, Shun Lu
|
Frequencies of ALK Rearrangements in Lung Adenocarcinoma Subtypes: a Study of 2299 Chinese Cases
|
SpringerPlus
|
2016
|
2016,5: 894
|
|
,Zhengbo Song,Shunfang Yang, et al.
|
Everolimus and zoledronic acid-a potential synergistic treatment for lung adenocarcinoma bone metastasis
|
Acta Biochim Biophys Sin
|
2014
|
2014,46(9):792-801
|
|
, Zhengbo Song, et al.
|
EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma
|
Journal of Cancer Research and Clinical Oncology
|
2012
|
2012,138(8):1421-1425
|
|
, Zhengbo Song, Shun Lu ,et al.
|
Chinese Pediatric and Adolescent Primary Tracheobronchial Tumors:a Hospital- Based Study
|
Pediatric Surgery International
|
2011
|
2011,27(7):721-726
|
|
Zhengbo Song,, Shun Lu ,et al.
|
Third-Line Therapy for Advanced Non-Small-Cell Lung Cancer Patients: Feasible Drugs for Feasible Patients
|
Medical Oncology
|
2011
|
2011,28,S605-S612
|
|
, Zhi-wei Chen, Zhen Zhou, Shun Lu.,et al.
|
A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexedin Second-line Chemotherapy for Stage III b or IV Non-Small Cell Lung Cancer Patients in China.
|
CHEMOTHERAPY
|
2010
|
2010,56(6):472-477
|
|
Zhiwei Chen,, Shun Lu,et al.
|
Functional roles of PC-PLC and Cdc20 in the cell cycle, proliferation, and apoptosis
|
Cell Biochem Funct
|
2010
|
2010,28(4):249-57
|
|
,ZiMing Li,Shun Lu,et al.
|
The Effect of Cetuxmab Alone and in Combination With Endostatin on Vascular Endothelial Growth Factor and Interleukin-8 Expression in Human Lung Adenocarcinoma Cells
|
Current Therapeutic Research
|
2009
|
2009,70(2):116-128
|
|